酪酸梭菌联合四联疗法治疗幽门螺杆菌阳性胃溃疡的作用机制研究

摘要：目的  观察酪酸梭菌（Cb）联合四联疗法治疗幽门螺杆菌（Hp）阳性胃溃疡的作用。方法  选取Hp阳性胃溃疡102例，采取随机双盲方法，将其分为观察组和对照组。前2周，观察组口服埃索美拉唑镁肠溶片+枸橼酸铋剂钾片+阿莫西林胶囊+左氧氟沙星片+酪酸梭菌活菌胶囊，对照组在上述四联疗法基础上加空白胶囊；后2周，停用抗生素和枸橼酸铋剂钾片。疗程结束后1个月，比较两组治疗有效率、Hp根除率、不良反应发生率。结果  观察组有效率为89.46%，对照组为76.00%，经χ2检验，差异无统计学意义（P >0.05）。观察组HP根除率为82.69%，对照组HP为64.00%，经χ2检验，差异有统计学意义（P <0.05）。观察组不良反应发生率为11.54%，对照组为18.00%，经χ2检验，差异无统计学意义（P >0.05）。结论  Cb联合四联疗法能够提高胃溃疡Hp根除率。

     

Efficacy and safety of modified tetracycline dosing in a quadruple therapy for Helicobacter pylori: A retrospective single center study

BACKGROUND Although highly effective as a component of Helicobacter pylori(H. pylori) treatment regimen, tetracycline is associated with a high incidence of medicationrelated adverse events. Modified dosing of tetracycline as part of quadruple therapy may improve safety while providing comparable eradication rates.AIM To evaluate the efficacy and safety of modified dosing of tetracycline in patients receiving tetracycline and furazolidone-containing quadruple therapy in patients with H. pylori i...     

Effect of fucoidan on gut microbiota and its clinical efficacy in Helicobacter pylori eradication: A randomized controlled trial

Objective

To assess the clinical efficacy of fucoidan-assisted standard quadruple therapy (SQT) in Helicobacter pylori (H. pylori) eradication and the improvement of gut microbiota.

Methods

An open-label randomized controlled trial was conducted at the Affiliated Hospital of Qingdao University in Shandong Province, China. Ninety patients who tested positive for H. pylori were randomized to the standard quadruple therapy (SQT) group (SQ), SQT + fucoidan combination group (SF), and fucoidan + sequential SQT group (FS), respectively. Stool samples were collected for gut microbiota composition at baseline and after treatment.

Results

After H. pylori eradication, the relative abundances of most conditional pathogens in the SQ decreased, while those of several beneficial bacteria increased or decreased (P < 0.05). In FS, the abundances of most beneficial bacteria increased gradually from baseline to week 12, while those of the conditional pathogens decreased (P < 0.05). The abundance of Bifidobacterium had a decreasing trend in SQ, but remained unchanged in SF and increased in FS (P < 0.05). The abundances of most beneficial bacteria were significantly higher in FS than in SQ and SF (P < 0.05). Addition of fucoidan enhanced symptom improvement during H. pylori eradication compared with SQT alone.

Conclusions

Fucoidan considerably improved gut dysbiosis during SQT for H. pylori eradication. Gut microbiota can be maintained by the addition of fucoidan before eradication therapy with SQT rather than by concomitant addition with therapy. Fucoidan-assisted SQT could relieve gastrointestinal symptoms during H. pylori eradication.     

双歧杆菌三联活菌肠溶胶囊联合碱式水杨酸铋治疗小儿反复腹泻的临床研究

目的 探讨双歧杆菌三联活菌肠溶胶囊联合碱式水杨酸铋治疗小儿反复腹泻的临床疗效。方法 选取2019年1月—2021年1月在河北中石油中心医院儿科住院治疗的150例腹泻患儿，按照随机数字表法分为对照组和治疗组，每组各75例。对照组患儿口服碱式水杨酸铋干混悬剂，1包/次，3次/d。治疗组患者在对照组基础上口服双歧杆菌三联活菌肠溶胶囊，3粒/次，2次/d。两组连续用药7 d。观察两组的临床疗效、症状缓解时间，比较两组治疗前后肠道菌群数量、血清细胞因子水平。结果 治疗后，治疗组总有效率98.67%，显著高于对照组的86.67%（P＜0.05）。治疗后，治疗组出现发热、乏力、食欲不振、大便次数增多缓解时间均显著短于对照组（P＜0.05）。治疗后，两组乳杆菌属、肠球菌属数量均较治疗前显著提高，酵母样真菌数量显著降低（P＜0.05）；治疗后，治疗组患儿肠道菌群数量改善优于对照组（P＜0.05）。治疗后，两组白细胞介素-10（IL-10）、白细胞介素-6（IL-6）、肿瘤坏死因子-α水平均较治疗前显著降低（P＜0.05）；治疗后，治疗组血清炎性因子水平低于对照组（P＜0.05）。结论 双歧杆菌三联活菌肠溶胶囊联合碱式水杨酸铋治疗小儿反复腹泻疗效确切，可有效改善患儿腹泻症状，改善肠道菌群数量，减弱肠道内炎症反应，且安全有效，值得临床推广应用。     

复方谷氨酰胺联合双歧三联活菌制剂治疗肠易激综合征41例

肠易激综合征是一种常见的功能性肠病,病因较多;腹泻型是其较多的一种类型;单一药物治疗效果欠佳。现应用复方谷氨酰胺联合双歧三联活菌制剂治疗,取得了明显疗效。1资料和方法1·1入选病例所选病例为本院2001年8月至2005年2月消化专科及普通门诊患者82例,男38例,女44例,年龄16~72岁,平均年龄41·5岁,入选病例均符合2000年罗马消化疾病会议所订Ⅱ诊断标准,且具备以下条件:排除肝、胆、胰等疾病引起的疾病;排除饮食、手术因素;经肠镜排除器质性疾病;能配合治疗和随访。按安全随机取样法将82例分为治疗组41例,对照组41例,两组病人在年龄、性别…